... WhatsApp

A Daily Pill Shows Promise for Treating Ulcerative Colitis in East Asia

You are here >> Home > Latest Updates > GI & HPB > Ulcerative Colitis > A Daily…

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia DOI 10.1016S2468-1253(25)00198-0

Ulcerative colitis (UC) is a long-term illness that causes inflammation in the large intestine. Many people with moderate to severe UC struggle to find treatments that work well and are easy to take. A new study looked at a once-a-day pill called etrasimod to see if it could help.

The study included 340 patients from China, Taiwan, and South Korea. These people had UC that didn’t respond well to other treatments. They were given either etrasimod or a placebo (a pill with no medicine) for 12 weeks. If their symptoms improved, they were re-randomized to keep taking etrasimod or placebo for another 40 weeks.

By week 12, one in four people taking etrasimod felt better and showed signs of healing in the gut, compared to just 1 in 20 people taking the placebo. The results were even better for those who stayed on etrasimod for the full study period—nearly half were still doing well at 40 weeks.

Side effects were mostly mild. The most common issues were liver enzyme changes and mild infections. Serious problems were rare, and very few people had to stop taking the medicine because of side effects.

This study shows that etrasimod could be a helpful option for people with UC who want an effective treatment that’s easy to take. Talk to your doctor to see if new treatments like this might be right for you.

Rate this post
Robotic Cancer Surgery

Exclusive Health Tips and Updates

Best robotic cancer surgery in Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.